Pharmaceuticals France

France Shingles Vaccines Market Analysis, 2024–2034

France Shingles Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $113.6 Mn Estimated value
Estimate 2025 $120.7 Mn 2.3% of the global market
Projected 2034 $207.4 Mn 71.8% Adds $86.7 Mn over 9 forecast years
CAGR 2025–2034 6.2% Faster than 41% of 180 Pharmaceuticals markets here
Key players 5
  • France is 2.34% of the global market.
  • In Europe, the largest is Germany at $182.6 Mn.
  • Fastest growing: Russia at 6.6% a year.
  • France ranks 3rd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$86.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Shingles Vaccines Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $113.6 Mn — —
2025 (base) $120.7 Mn +$7.0 Mn —
2026 (forecast) $128.2 Mn +$7.5 Mn +6.2%
2027 (forecast) $136.1 Mn +$7.9 Mn +12.8%
2028 (forecast) $144.5 Mn +$8.4 Mn +19.8%
2029 (forecast) $153.5 Mn +$9.0 Mn +27.2%
2030 (forecast) $163.0 Mn +$9.5 Mn +35.1%
2031 (forecast) $173.1 Mn +$10.1 Mn +43.5%
2032 (forecast) $183.9 Mn +$10.7 Mn +52.4%
2033 (forecast) $195.3 Mn +$11.4 Mn +61.8%
2034 (forecast) $207.4 Mn +$12.1 Mn +71.8%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $5.15 Bn
  2. North America $2.66 Bn
  3. US $1.98 Bn
  4. Europe $1.00 Bn
  5. APAC $976.7 Mn
  6. China $468.3 Mn
  7. Canada $395.1 Mn
  8. Japan $351.7 Mn
  9. Latin America $261.4 Mn
  10. Middle East $210.1 Mn
  11. Germany $182.6 Mn
  12. Italy $140.2 Mn
  13. Brazil $135.4 Mn
  14. France (this report) $120.7 Mn
  15. UK $117.4 Mn
  16. Saudi Arabia $100.2 Mn
  17. Ecuador $96.8 Mn
  18. India $100.6 Mn
  19. Africa $90.2 Mn
  20. Spain $86.6 Mn
  21. Mexico $70.3 Mn
  22. Australia $66.6 Mn
  23. New Zealand $57.6 Mn
  24. Russia $53.6 Mn
  25. South Africa $30.2 Mn
  26. UAE $25.7 Mn
  27. Egypt $16.3 Mn
  28. Philippines $10.2 Mn
  29. Hong Kong $9.4 Mn
  30. Malaysia $9.1 Mn
  31. Singapore $6.7 Mn
  32. Thailand $6.0 Mn
  33. Kenya $3.1 Mn

The France Shingles Vaccines Market Analysis Executive Summary

Shingles vaccines prevent herpes zoster, a painful rash caused when the chickenpox virus wakes up again, mostly in older adults.

Key segments of the shingles Vaccines market include type (Recombinant Vaccines and Live Attenuated Vaccines) and age (50-64 Years, 65 Years and Above and Immunocompromised Adults).

France Shingles Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the shingles Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the shingles Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the shingles Vaccines market.

Competitive Landscape for Shingles Vaccines Market in France

The shingles Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Shingles Vaccines Market in France

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for shingles Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Shingles Vaccines right now, from free public sources.

Clinical trials

5 active trials in France

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. GSK PLC 12 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Suzhou Abogen Biosciences Co., Ltd. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Guangzhou Patronus Biotech Co., Ltd. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Sinovac Biotech Co., Ltd 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. CSPC Megalith Biopharmaceutical Co.,Ltd. 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 33 papers since 2021 (worldwide)

  1. Recombinant shingles vaccination and the risk of cardiovascular events. Nature medicine, 2026
  2. Determinants and mitigation strategies of vaccine hesitancy toward routine immunisations recommended for older adults: a systematic review. Age and ageing, 2026
  3. FDA blocks publication of studies showing covid and shingles vaccines to be safe. BMJ (Clinical research ed.), 2026
  4. Vaccine adherence among adult cancer survivors in the United States. Journal of the National Cancer Institute, 2026
  5. A randomized assessment of the impact of 'Those Nerdy Girls' newsletters on adult vaccination outcomes. PloS one, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Shingles Vaccines in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]

Questions, answered with public data

How many clinical trials on Shingles Vaccines are running in France?
5 studies are recruiting, active or about to start in France.[4]
How much research is published on Shingles Vaccines?
PubMed lists 33 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Shingles Vaccines in France? Our analysts can size it for your plan. Talk to us See the public data Measles vaccine for every country, free. Open the Public Health Dashboard

From our blog

Bone and Joint Health: Supplements for an Ageing Population1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence… Eye Health Supplements: Screens, Ageing and Vision2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a… Collagen Supplements: Skin, Joints and Real EvidenceCollagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in France

See all
Same topic, other categories

Related on vaccines and geriatric

See the topic